Systems biology driven models coupled with whole-genome RNAi screens in HER2 transformed BC cell lines revealed the IL6/JAK2/STAT3 axis as a master regulator pathway underlying the resistance phenotype against trastuzumab (Rodriguez-Barrueco et al., 2015). This evidence concerns the gene ERBB2 and breast cancer.